Trial Profile
A 2-year extension to a 1-year multicenter, randomized, open label, parallel group study of the safety, tolerability and efficacy of two doses (1.5 and 3 mg/day) of everolimus with steroids and optimized administration of cyclosporine in de novo renal transplant recipients.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 11 Nov 2011
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Ciclosporin; Corticosteroids
- Indications Renal transplant rejection
- Focus Registrational; Therapeutic Use
- Sponsors Novartis
- 01 Nov 2011 Actual end date (August 2005) added as reported by ClinicalTrials.gov.
- 03 Oct 2007 New trial record.